Vyome gets USPTO notice of allowance for VT-1908 topical mycophenolate patent application
HIND•Vyome received a USPTO Notice of Allowance for a U.S. patent application covering VT-1908, its topical ophthalmic mycophenolate program. The company is initially developing the candidate for anterior uveitis and estimates the broader ocular inflammation market could exceed $20 billion by 2035.
1. Patent application allowed
The allowed claims cover formulations and methods of use for inflammatory diseases, supporting intellectual property protection around VT-1908’s development plans. Vyome is initially developing the candidate for anterior uveitis as a potential steroid-sparing therapy.
